These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7351114)

  • 21. Stereoselective disposition and glucuronidation of propranolol in humans.
    Silber B; Holford NH; Riegelman S
    J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Massive propranolol metabolite retention during maintenance hemodialysis.
    Stone WJ; Walle T
    Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative account of propranolol metabolism in urine of normal man.
    Walle T; Walle UK; Olanoff LS
    Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics and cardiac effects of propranolol in humans.
    Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
    Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
    Lankford SM; Maskasame C; Bai SA
    Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propranolol disposition after acute myocardial infarction.
    Paxton JW; Norris RM
    Clin Pharmacol Ther; 1984 Sep; 36(3):337-42. PubMed ID: 6467793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of propranolol, 4-hydroxypropranolol and propranolol glycol in human plasma.
    Schneck DW; Pritchard JF; Hayes AH
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):3-12. PubMed ID: 432438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration.
    Drummer OH; McNeil J; Pritchard E; Louis WJ
    J Pharm Sci; 1981 Sep; 70(9):1030-2. PubMed ID: 6101148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine and plasma propranolol.
    Andreasen F; Jakobsen P; Kornerup HJ; Pedersen EB; Pedersen OL
    Clin Pharmacol Ther; 1983 Jan; 33(1):10-8. PubMed ID: 6848294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma concentrations of propranolol and 4-hydroxy-propranolol at steady-state in neurological patients: intersubject and intrasubject correlations with dose.
    Albani F; Riva R; Baldrati A; Cortelli P; Perucca E; Procaccianti G; Baruzzi A
    Int J Clin Pharmacol Res; 1984; 4(1):19-23. PubMed ID: 6469429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of individual differences in gastric emptying to variability in plasma propranolol concentrations.
    Castleden CM; George CF; Short MD
    Br J Clin Pharmacol; 1978 Feb; 5(2):121-2. PubMed ID: 619945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
    Bai SA; Wilson MJ; Walle UK; Walle T
    J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites.
    Walle T; Fagan TC; Walle UK; Oexmann MJ; Conradi EC; Gaffney TE
    Clin Pharmacol Ther; 1981 Dec; 30(6):790-5. PubMed ID: 7307427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.
    Wargin WA; Sawchuk RJ; McBride JW; McCoy HG; Rylander ML
    Eur J Drug Metab Pharmacokinet; 1982; 7(3):183-9. PubMed ID: 7173272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Oct; 67(10):1360-3. PubMed ID: 702279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics and biotransformation of lormetazepam. II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect.
    Hümpel M; Nieuweboer B; Milius W; Hanke H; Wendt H
    Clin Pharmacol Ther; 1980 Nov; 28(5):673-9. PubMed ID: 6108174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.